Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabian Frontzek

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
British Journal of Haematology|April 1, 2022
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trialGeorg Hess, Andreas Hüttmann, Mathias Witzens-Harig, et al.
Histopathology|November 9, 2020
Cytokeratin expression in plasmablastic lymphoma - a possible diagnostic pitfall in the routine work-up of tumoursKatrin S Huettl, Annette M Staiger, Heike Horn, et al.
Leukemia|January 5, 2023
Molecular profiling of EBV associated diffuse large B-cell lymphomaFabian Frontzek, Annette M Staiger, Ramona Wullenkord, et al.
Blood Advances|January 30, 2023
Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysisCatherine Thieblemont, Bettina Altmann, Fabian Frontzek, et al.
The Lancet. Haematology|March 5, 2021
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trialFabian Frontzek, Marita Ziepert, Maike Nickelsen, et al.
Leukemia|August 16, 2024
Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaborationFabian Frontzek, Loïc Renaud, Ulrich Dührsen, et al.
Blood Advances|April 9, 2025
The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potentialMiriam Verdú-Bou, Maria Joao Baptista, Marcelo Lima Ribeiro, et al.
Blood|June 20, 2025
Somatic IRF4 Mutations and Thymic Tropism in Primary Mediastinal Large B-cell LymphomaShinya Rai, Gerben Duns, Fabian Frontzek, et al.
Nature Communications|September 1, 2021
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphomaFabian Frontzek, Annette M Staiger, Myroslav Zapukhlyak, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
British Journal of Haematology|April 1, 2022
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trialGeorg Hess, Andreas Hüttmann, Mathias Witzens-Harig, et al.
Histopathology|November 9, 2020
Cytokeratin expression in plasmablastic lymphoma - a possible diagnostic pitfall in the routine work-up of tumoursKatrin S Huettl, Annette M Staiger, Heike Horn, et al.
Leukemia|January 5, 2023
Molecular profiling of EBV associated diffuse large B-cell lymphomaFabian Frontzek, Annette M Staiger, Ramona Wullenkord, et al.
Blood Advances|January 30, 2023
Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysisCatherine Thieblemont, Bettina Altmann, Fabian Frontzek, et al.
The Lancet. Haematology|March 5, 2021
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trialFabian Frontzek, Marita Ziepert, Maike Nickelsen, et al.
Leukemia|August 16, 2024
Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaborationFabian Frontzek, Loïc Renaud, Ulrich Dührsen, et al.
Blood Advances|April 9, 2025
The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potentialMiriam Verdú-Bou, Maria Joao Baptista, Marcelo Lima Ribeiro, et al.
Blood|June 20, 2025
Somatic IRF4 Mutations and Thymic Tropism in Primary Mediastinal Large B-cell LymphomaShinya Rai, Gerben Duns, Fabian Frontzek, et al.
Nature Communications|September 1, 2021
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphomaFabian Frontzek, Annette M Staiger, Myroslav Zapukhlyak, et al.
Pageof 2